Pharmaceutical Non-Active Ingredients TRIZ Cases

Conjugate molecules link COX-2 inhibitors to cannabinoids via ester-amide linkers.

Sub-ambient cooling precipitates cyclodextrin polymer conjugates, eliminating impeller adhesion and manual stripping.

Film coatings and optimized particle sizes reduce sublimation losses in delayed release dosage forms.

Tri-functional reagents enable simultaneous release and functionalization, resolving heterogeneity in antibody drug conjugates.

Heterobifunctional degrader-antibody conjugates target TM4SF1 to induce selective protein degradation.

Removing glycosylation from the Fc portion of an anti-CD56 antibody-drug conjugate reduces neutropenia risk while maintaining tumor targeting.

Radio frequency heating detaches the treatment from the carrier at the target site, resolving non-specific distribution issues.

Modified folate analogs attached to oligonucleotides enhance cellular penetration and stability against exonucleases.

A rivastigmine transdermal patch merges the drug and adhesive into one layer using skin penetration enhancers.

Ion pairing bridges the solubility gap of lipoic acid derivatives, enabling selective targeting of cancer cell metabolism and tumor reduction.

Self-assembling peptide-drug nanotubes shield unstable camptothecin from water and serum proteins, preventing lactone ring hydrolysis.

Merging auristatin ADCs with PI3K or MEK inhibitors overcomes single-agent efficacy limits.

Antigen-adjuvant microparticle complexes use amphiphilic polymers to encapsulate proteins within hydrophobic segments.

A two-stage wet granulation process combines specific disintegrator components to form stable granules.

A natural binder composition blends guar gum, xanthan gum, and plant fibers to enhance tablet hardness and compressibility.

Poly(2-oxazine) block copolymers resolve cytocompatibility trade-offs by forming shear-thinning hydrogels with adjustable gelation temperatures.

Microcells containing aqueous formulations stabilize hydrophilic actives and prevent crystallization while enabling controlled release profiles.

Reversible masking of cationic polymers reduces in vivo toxicity while maintaining membrane activity for efficient nucleic acid delivery.

Oxidized phospholipid liposomes extend ocular drug release to 200 days, reducing injection frequency and infection risks.

Synthetic 3′-azido NAD+ enables click chemistry conjugation of GCSF to PAR polymers, resolving targeted delivery limitations while preserving biocompatibility.

Optimizing hydroxypropyl group content and viscosity prevents blocking under high temperature and humidity.

DEAEMA-MMA copolymer coatings prevent premature drug release in neutral pH and maintain redispersibility for taste masking.

Isopropanol replaces ethanol to dissolve cholesterol lipid mixtures, preventing precipitation and reducing drying time while lowering residual solvent toxicity.

Engineered extracellular vesicles transport antisense oligonucleotides across the blood-brain barrier via LAT1-mediated uptake to treat brain disorders.

Saturated C-ring pyrrolobenzodiazepine dimers resolve the trade-off between high reactivity and tumour selectivity, improving therapeutic index.

Incorporating L-cysteine and polymeric binders into atrasentan formulations prevents oxidation, ensuring long-term stability for commercial distribution.

Poly(ethylene imine)-based copolymers bond to and release genetic material through segmented PEI and 2-oxazoline units.

A centrosymmetric eight-arm polyethylene glycol derivative increases drug loading capacity through precise molecular weight control.

Lipid nanoparticles incorporate targeting peptides to deliver cargo to muscle cells, avoiding viral vector toxicity and immune responses.

Comb-type polymer aggregates solubilize anticancer agents in hydrophobic cores while attaching targeting ligands to specific tumor cells.

Galactosyltransferase enzymes modify terminal GlcNAc moieties on glycoproteins, replacing unstable maleimide linkages with stable beta-galactoside bonds.

Ultra-low crosslinked microgels mimic platelets to resolve trade-offs in hemostasis effectiveness.

Multiple terminal hydroxyl groups create a robust hydration shell that lowers antigenicity and simplifies purification compared to reverse-phase chromatography.

A water-soluble reverse thermal gel transitions from liquid to gel upon heating, enabling controlled therapeutic agent release.

Water reactive agaroid formulations shift gelation below body temperature, eliminating external heating or cooling equipment requirements.

Sodium decanoate mediates hydrophobic reagent solubility, eliminating organic co-solvents that cause protein aggregation during antibody-drug conjugation.

A bottlebrush polymer-oligonucleotide conjugate enhances in vivo stability and transfection efficiency through a sequence-defined backbone structure.

Magnetic microcapsule assemblies overcome passive diffusion limits by using iron oxide nanoparticles for targeted therapeutic agent transport.

Phosphatidylcholine and medium-chain triglycerides form micellar structures to solubilize lipophilic dietary supplements.

A Factor IX moiety-polymer conjugate uses a hydrolyzable carbamate bond to release the active agent, extending half-life and reducing immunogenicity.

Acid-heat treatment followed by extrusion yields low-viscosity starch with reduced reducing sugars, avoiding costly spray-drying.

Standardized ultrapure water extraction combined with tangential flow filtration reduces drying time and impurities while maintaining active substance yield.

Gellan gum and starch composite shells prevent oil leakage while ensuring rapid disintegration in gastric fluids.